BNP Paribas Financial Markets’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-7,573
| Closed | -$28K | – | 4418 |
|
|
2017
Q4 | $28K | Buy |
7,573
+4,228
| +126% | +$17.3K | ﹤0.01% | 3899 |
|
|
2017
Q3 | $13.7K | Sell |
3,345
-248
| -7% | -$949 | ﹤0.01% | 3777 |
|
|
2017
Q2 | $13.3K | Buy |
+3,593
| New | +$14.3K | ﹤0.01% | 3862 |
|
|
2016
Q1 | – | Sell |
-3,187
| Closed | -$42.4K | – | 3386 |
|
|
2015
Q4 | $42.4K | Sell |
3,187
-114
| -3% | -$1.96K | ﹤0.01% | 2922 |
|
|
2015
Q3 | $54.3K | Buy |
3,301
+1,882
| +133% | +$38.6K | ﹤0.01% | 2796 |
|
|
2015
Q2 | $31.8K | Buy |
1,419
+1,048
| +282% | +$16.6K | ﹤0.01% | 2753 |
|
|
2015
Q1 | $3.63K | Buy |
+371
| New | +$3.64K | ﹤0.01% | 3312 |
|
|
2014
Q4 | – | Sell |
-793
| Closed | -$9.13K | – | 3724 |
|
|
2014
Q3 | $9.13K | Buy |
793
+572
| +259% | +$8.74K | ﹤0.01% | 3631 |
|
|
2014
Q2 | $4.3K | Hold |
221
| – | – | ﹤0.01% | 2662 |
|
|
2014
Q1 | $3.8K | Hold |
221
| – | – | ﹤0.01% | 2478 |
|
|
2013
Q4 | $2.34K | Buy |
+221
| New | +$2.47K | ﹤0.01% | 3585 |
|
BNP Paribas Financial Markets's CASC Position: Q1 2018 in Review
BNP Paribas Financial Markets sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 7,573 shares — an estimated $28K sold.
BNP Paribas Financial Markets first reported a position in CASC in Q4 2013 and held it in 11 quarters. The position peaked at $54.3K in Q3 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- BNP Paribas Financial Markets reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- BNP Paribas Financial Markets sold 7,573 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $28K.
- BNP Paribas Financial Markets first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 11 quarters.
- BNP Paribas Financial Markets's Cascadian Therapeutics, Inc. position peaked at $54.3K in Q3 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2018, filed 11 May 2018.